#biotechnology
Related Stories (20)
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen - Reuters
Novartis strikes up to $7.8 billion mRNA deal with China's Abogen Reuters
October 2, 2026China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters
China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion Reuters
September 24, 2026Anthropic says Claude AI helped discover novel enzyme system - Reuters
Anthropic says Claude AI helped discover novel enzyme system Reuters
September 23, 2026Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds - Reuters
Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds Reuters
September 15, 2026Scholar Rock gets first FDA nod for rare muscle-wasting disease - Reuters
Scholar Rock gets first FDA nod for rare muscle-wasting disease Reuters
September 11, 2026Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology - Reuters
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology Reuters
September 2, 2026Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push - Reuters
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push Reuters
August 31, 2026Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough - Reuters
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough Reuters
August 28, 2026Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval - Reuters
Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval Reuters
August 26, 2026The Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use? - Reuters
The Merck/Moderna cancer vaccine: How does it work and what are potential barriers to wide use? Reuters
August 25, 2026Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder - Reuters
Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder Reuters
August 19, 2026Moderna, Merck breakthrough could usher in wave of cancer vaccines - Reuters
Moderna, Merck breakthrough could usher in wave of cancer vaccines Reuters
August 19, 2026Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Lawsuit against Bristol Myers over delayed cancer drug is revived Reuters
August 13, 2026US FDA approves Replimune's skin cancer drug after prior rejections - Reuters
US FDA approves Replimune's skin cancer drug after prior rejections Reuters
August 6, 2026Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition - Reuters
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition Reuters
August 6, 2026US FDA approves first mRNA flu shot from Moderna - Reuters
US FDA approves first mRNA flu shot from Moderna Reuters
August 6, 2026Tempus to buy cancer test maker Personalis for $1.5 billion - Reuters
Tempus to buy cancer test maker Personalis for $1.5 billion Reuters
July 20, 2026Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal - Reuters
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Reuters
July 16, 2026Vertex to buy Crinetics for $10 billion in rare-diseases push - Reuters
Vertex to buy Crinetics for $10 billion in rare-diseases push Reuters
July 6, 2026Related Pages (20)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Amgen owes $20.2 million in antibody patent lawsuit, US jury says
(()=>{"use strict";window.initData=window.initData||{},window.initData.block_widgetbar=function(i,t,a,n,e){function w(a){const w={resizerBridge:t.allocate({areaName:"right"}),affectsLayout:()=>!0,adap
China’s WuXi sues US over allegations it supports Beijing’s military
By Nikita Maria Jino, Kumar Tanishk and Jonathan Stempel June 11 (Reuters) – A Chinese biotechnology company sued the U.S. government on Thursday over being placed on a list of businesses from China
China’s WuXi sues US over allegations it supports Beijing’s military
By Nikita Maria Jino, Kumar Tanishk and Jonathan Stempel June 11 (Reuters) – A Chinese biotechnology company sued the U.S. government on Thursday over being placed on a list of businesses from China
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
Isomorphic Labs Eyes $2 Billion Raise as AlphaFold's Drug Discovery Ambitions Enter a New Phase
Isomorphic Labs, the drug discovery company spun out of Google DeepMind in 2021, is in advanced discussions to raise more than $2 billion in a new funding round, according to Bloomberg. Thrive Capital
Isomorphic Labs raises $2.1bn Series B
According to Sifted, DeepMind spinout Isomorphic Labs has raised $2.1bn in a Series B round led by Thrive Capital. Sifted reports the round included the UK's Sovereign AI Fund, Abu Dhabi's MGX, Alphab